Concomitant_JJ
downregulation_NN
of_IN
IgH_NN
3_CD
'_POS
enhancer_NN
activity_NN
and_CC
c-myc_NN
expression_NN
in_IN
a_DT
plasmacytoma_NN
x_NN
fibroblast_NN
environment_NN
:_:
implications_NNS
for_IN
dysregulation_NN
of_IN
translocated_VBN
c-myc_NN
._.

Regulation_NN
of_IN
immunoglobulin_NN
heavy_JJ
chain_NN
-LRB-_-LRB-
IgH_NN
-RRB-_-RRB-
gene_NN
expression_NN
is_VBZ
controlled_VBN
by_IN
a_DT
B_NN
cell-specific_JJ
promoter_NN
,_,
intronic_JJ
enhancer_NN
and_CC
additional_JJ
B_NN
cell-specific_JJ
enhancer_NN
elements_NNS
identified_VBN
recently_RB
in_IN
the_DT
3_CD
'_POS
end_NN
of_IN
the_DT
IgH_NN
locus_NN
._.

One_CD
of_IN
the_DT
latter_JJ
elements_NNS
,_,
the_DT
IgH_NN
3_CD
'_POS
enhancer_NN
,_,
is_VBZ
of_IN
particular_JJ
interest_NN
:_:
-LRB-_-LRB-
1_LS
-RRB-_-RRB-
it_PRP
is_VBZ
B_NN
cell-specific_JJ
and_CC
active_JJ
only_RB
in_IN
late_JJ
B_NN
cell_NN
development_NN
;_:
-LRB-_-LRB-
2_LS
-RRB-_-RRB-
in_IN
rodent_JJ
plasmacytomas_NNS
and_CC
in_IN
some_DT
human_JJ
Burkitt_NN
's_POS
lymphomas_NNS
it_PRP
is_VBZ
part_NN
of_IN
a_DT
locus_NN
control_NN
region_NN
-LRB-_-LRB-
LCR_NN
-RRB-_-RRB-
that_WDT
is_VBZ
involved_VBN
in_IN
deregulation_NN
of_IN
the_DT
c-myc_NN
oncogene_NN
as_IN
a_DT
result_NN
of_IN
translocation_NN
into_IN
the_DT
IgH_NN
locus_NN
;_:
and_CC
-LRB-_-LRB-
3_LS
-RRB-_-RRB-
it_PRP
has_VBZ
been_VBN
implicated_VBN
in_IN
the_DT
mechanisms_NNS
that_WDT
control_VBP
Ig_NN
gene_NN
class_NN
switch_NN
recombination_NN
._.

We_PRP
have_VBP
used_VBN
a_DT
somatic_JJ
cell_NN
hybridization_NN
approach_NN
to_TO
genetically_RB
analyze_VB
regulation_NN
of_IN
the_DT
activity_NN
of_IN
the_DT
IgH_NN
3_CD
'_POS
enhancer_NN
._.

When_WRB
mouse_NN
MPC11_NN
plasmacytoma_NN
cells_NNS
,_,
in_IN
which_WDT
the_DT
IgH_NN
3_CD
'_POS
enhancer_NN
is_VBZ
active_JJ
,_,
are_VBP
fused_VBN
with_IN
fibroblasts_NNS
,_,
Ig_NN
expression_NN
is_VBZ
extinguished_VBN
at_IN
the_DT
level_NN
of_IN
transcription_NN
._.

Here_RB
we_PRP
show_VBP
that_IN
in_IN
a_DT
MPC11_NN
plasmacytoma_NN
x_NN
fibroblast_NN
environment_NN
,_,
the_DT
IgH_NN
3_CD
'_POS
enhancer_NN
is_VBZ
transcriptionally_RB
inactive_JJ
._.

Furthermore_RB
,_,
we_PRP
demonstrate_VBP
that_IN
binding_VBG
of_IN
several_JJ
B_NN
cell-specific_JJ
transcription_NN
factors_NNS
,_,
essential_JJ
for_IN
IgH_NN
3_CD
'_POS
enhancer_NN
activity_NN
,_,
is_VBZ
lacking_JJ
,_,
which_WDT
may_MD
explain_VB
3_CD
'_POS
enhancer_NN
inactivity_NN
,_,
although_IN
the_DT
binding_NN
of_IN
repressors_NNS
can_MD
not_RB
be_VB
excluded_VBN
._.

Moreover_RB
,_,
the_DT
high_JJ
expression_NN
level_NN
of_IN
c-myc_NN
,_,
characteristic_JJ
of_IN
the_DT
parental_JJ
MPC11_NN
cells_NNS
carrying_VBG
the_DT
t_NN
-LRB-_-LRB-
12_CD
;_:
15_CD
-RRB-_-RRB-
translocation_NN
,_,
is_VBZ
down-regulated_VBN
in_IN
the_DT
hybrids_NNS
to_TO
that_DT
in_IN
unfused_JJ
fibroblasts_NNS
._.

Therefore_RB
,_,
inactivation_NN
of_IN
the_DT
IgH_NN
3_CD
'_POS
enhancer_NN
is_VBZ
a_DT
multifactorial_JJ
process_NN
affecting_VBG
several_JJ
transcription_NN
factors_NNS
that_WDT
control_VBP
the_DT
cell-specific_JJ
and_CC
developmental_JJ
activity_NN
of_IN
the_DT
enhancer_NN
._.

